|
|
Throughout 2020, the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) was challenged to respond to the COVID-19 pandemic while still working to bring safe and effective new drug therapies for a range of other diseases and conditions to patients in need. Today I’d like to share information on the new drug therapy approval successes we achieved during 2020 despite the unprecedented challenges caused by the pandemic.
In 2020, we approved a wide variety of new drugs never before marketed in the United States, known as "novel" drugs, along with a range of new approvals containing active ingredients already on the market put to new and innovative uses. Many will have a positive, and even life-saving impact, on countless patients' lives.
|
|
|
|
